Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a PO1 submission
Checked against the public recordLast updated Dec 13, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Wisconsin, Madison
- Interventions being studied
- Procedure: PET-imaging with CuATSM; Procedure: PET Imaging; Procedure: PET CuATSM; Procedure: PET imaging; Procedure: PET imaging with CuATSM; Procedure: PET imaging with CuATSM
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Able to tolerated a PET/CT scan * Age 18 or older * Patient being considered for XRT for treatment of their cancer * Able to provide written informed consent Exclusion Criteria: * severe claustrophobia or inability to tolerate the PET scan * pregnant or breastfeeding women * Patients that need supplemental oxygen * Patients enrolled in experimental treatments
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Wisconsin Hospital and ClinicsMadison, Wisconsin
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2019. Always confirm current availability with the study team.